ClinicalTrials.gg
RecruitingNCT06692712SPG50Updated Apr 20, 2026

Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.

A Phase 3 interventional study of MELPIDA in Hereditary Spastic Paraplegia Type 50, sponsored by Elpida Therapeutics SPC. Recruiting at 2 sites in 2 countries. Open to participants aged 4 Months to 72 Months. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Elpida Therapeutics SPC · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
4 Months to 72 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Paraplegia with a site in United States — 17 open to participants now, 18 under way, 2 of them phase 3. Paraplegia · United States.

Planned enrollment
25th of 54
24 · median 22
Started
2026
with 3 others
Phase 3
Only one
of the 64
Primary completion
2032-02
later than 17 of 17 live
Registered
58th of 64
by date
Lead sponsor
2 of 64
Elpida Therapeutics SPC

Among the 64 studies in Paraplegia with a site in United States, this one is the 25th largest by planned enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 3, reaches primary completion later than 17 of the 17 other live ones, and was the 58th registered.

Paraplegia

152 studies on the registry are indexed under Paraplegia; 37 are open to participants now.

Browse Paraplegia studies →

Open to participants now

17 of the 64 studies in Paraplegia with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Paraplegia studies recruiting now, 15 (47%) set no upper age limit and 14 (44%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 4 Months to 72 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Paraplegia with a site in United States, or all of them as a file.
02

Study summary

Phase 3, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of MELPIDA in individuals with Hereditary Spastic Paraplegia Type 50 (SPG50).

Read the detailed description

MELPIDA is an AAV9-based gene therapy vector that expresses the fully functional form of AP4M1 under the control of a synthetic promoter. MELPIDA will be delivered intrathecally and is designed to achieve stable, potentially life-long expression of AP4M1 in non-dividing cells. This clinical study is a pivotal open-label phase 3 study designed to assess safety and efficacy of MELPIDA in individuals with SPG50.

03

Conditions studied

  • Hereditary Spastic Paraplegia Type 50

Browse trials for

Keywords

  • SPG50
  • Spastic Paraplegia
  • Gene Therapy
  • Phase 3
04

Who can participate

Ages eligible
4 Months to 72 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For the treatment group

  • Male and females between the ages of 4 months to 72 months at the time of screening.
  • Molecularly-confirmed diagnosis of SPG50 (confirmed by a CLIA certified, CE-marked, or equivalent lab): Genomic DNA mutation analysis demonstrating bi-allelic pathogenic or likely pathogenic variants in the AP4M1 gene.
  • Subjects must have features of neurologic dysfunction by clinical history and physical examination.
  • Stable doses of concomitant medications such as anti-spasticity medications, anti-seizure medications, behavioral management medications, sleep medications, and special diets, supplements, or nutritional support for at least 3 months prior to Screening. If recent changes (\< 3 months) in medications, the subject may be allowed per Investigator judgement.
  • Parent/legal guardian willing to provide written for their child prior to participation in the study,
  • Subjects and caregivers must demonstrate the ability to travel to the study center. For the 30 days post treatment subjects must reside within 100 miles (approximately 160 km) of the clinical site.

For the control group

  • Male and females between the ages of 4 to 72 months at the time of screening.
  • A molecularly confirmed diagnosis of SPG47, SPG50 or SPG52 (confirmed by a CLIA certified, CE-marked, or equivalent lab). Genomic DNA mutation analysis demonstrating bi-allelic pathogenic variants in the AP4B1, AP4M1, or AP4S1 gene,
  • Subjects must have features of neurologic dysfunction by clinical history and physical examination.
  • Parent/legal guardian willing to provide written informed consent for their child prior to participation in the study.
  • Subject able to comply with all protocol requirements and procedures.
  • Subjects and caregivers must demonstrate the ability to travel to the study center.

Exclusion criteria

Exclusion

For the treatment group

  • Loss of one of the 8 major motor milestones within the last 12 months. Milestones defined as:

    • #24: Sit on mat: Maintain, arms free, 3 seconds
    • #44: 4 Point: Crawls or hitches forward 1.8m (6')
    • #53: Standing: Maintains, arms free, 3 seconds
    • #67: Standing: 2 hands held: walks forward 10 steps
    • #69: Standing: Walks forward 10 steps
    • #84: Standing: Holding 1 rail: walks up 4 steps, holding 1 rail, alternating feet
    • #85: Standing: Holding 1 rail: walks down 4 steps, holding 1 rail, alternating feet
    • #88: Standing on 15cm (6") step: Jumps off, both feet simultaneously
  • Inability to participate in the clinical evaluation as determined by the principal investigators.
  • abnormal laboratory values ( \< 6 or > 20 g/dL; white blood cell > 20,000 per cmm, count \< 100,000 per cmm; > ; GGT, , and AST or total > 1.5 × ULN, creatinine ≥ 1.5 mg/dL) prior to gene replacement therapy.
  • Presence of a concomitant medical condition (eg, scoliosis or bleeding disorder) that precludes a lumbar puncture or use of anesthetics for sedated procedures.
  • Documented cardiomyopathy or significant congenital heart abnormalities.
  • History of severe/life-threatening allergic reaction to sirolimus, tacrolimus, , or gadolinium.
  • Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer, or interactions with the agents.
  • Any item which would exclude the subject from being able to undergo MRI according to local institutional policy, or any other procedure.
  • The presence of significant AP-4 related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study.
  • Recent or planned elective surgical procedures (within 6 months) that would confound the scientific rigor or interpretation of results of the study.
  • Failure to obtain appropriate .
  • Reason to believe that the subject or parents of the subject will not comply with the study procedures outlined in the study protocol.
  • Have received an drug within 30 days prior to screening or plan to receive an investigational drug (other than gene therapy) during the study.
  • Enrollment and participation in another interventional clinical trial 90 days before first visit (screening).

For the control group

  • Loss of one of the 8 major motor milestones within the last 12 months. Milestones defined as:

    • #24: Sit on mat: Maintain, arms free, 3 seconds
    • #44: 4 Point: Crawls or hitches forward 1.8m (6')
    • #53: Standing: Maintains, arms free, 3 seconds
    • #67: Standing: 2 hands held: walks forward 10 steps
    • #69: Standing: Walks forward 10 steps
    • #84: Standing: Holding 1 rail: walks up 4 steps, holding 1 rail, alternating feet
    • #85: Standing: Holding 1 rail: walks down 4 steps, holding 1 rail, alternating feet
    • #88: Standing on 15cm (6") step: Jumps off, both feet simultaneously
  • Inability to participate in the clinical evaluation as determined by the principal investigators.
  • Any other situation that would exclude the subject from undergoing any other procedure required in this study.
  • The presence of significant AP-4 related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study.
  • Recent or planned elective surgical procedures that would confound the scientific rigor or interpretation of results of the study.
  • Failure to obtain appropriate informed consent.
  • Reason to believe that the subject or parents of the subject will not comply with the study procedures outlined in the study protocol.
  • Have received an investigational drug within 30 days prior to screening or plans to receive an investigational drug (other than gene therapy) during the study.
  • Enrollment and participation in another interventional clinical trial 90 days before first visit (screening).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    MELPIDA Treatment

    Eligible subjects (N=8) will receive a single open-label intrathecal administration of MELPIDA and follow up to week 260.

    Genetic: MELPIDA

  • No intervention
    Matched Prospective Concurrent Control Arm

    Approximately 16 untreated age- and disease- matched controls with confirmed AP-4-related disease (SPG47, SPG50, or SPG52) will be enrolled and attend study visits concurrent with the MELPIDA treatment arm.

Interventions

  • GeneticMELPIDA

    Gene Therapy agent

06

What researchers measure

Primary outcomes

  1. Gross Motor Function Measure (GMFM-88) Defined Major Milestones

    Change in total percent score of the 8 Major Motor Milestone Scores from baseline in treated group compared to change in total percent score of the 8 Major Motor Milestone Scores from baseline in untreated controls 1. #24: Sit on mat: Maintain, arms free, 3 seconds 2. #38: Prone: Creeps forward 1.8m (6') 3. #52: On the floor: Pulls to stand at large bench 4. #67: Standing: 2 hands held: walks forward 10 steps 5. #69: Standing: Walks forward 10 steps 6. #84: Standing: Holding 1 rail: walks up 4 steps, holding 1 rail, alternating feet 7. #85: Standing: Holding 1 rail: walks down 4 steps, holding 1 rail, alternating feet 8. #88: Standing on 15cm (6") step: Jumps off, both feet simultaneously

    Time frame: 156 weeks

Secondary outcomes

  1. Composite Endpoint Defined by the Win Ratio

    Composite Endpoint Defined by the Win Ratio using matching criteria after 156 Weeks of Follow-up of the 8 selected items and the raw scores of the Cognitive domain of the Bayley Scale of Infant and Toddler Development 4th Edition (Bayley-4).

    Time frame: 156 weeks

  2. Developmental Milestones- Bayley-4 Cognitive Domain

    Developmental Milestones- Bayley-4 Cognitive Domain-Change in Total Raw Score from Baseline

    Time frame: 156 weeks

  3. Gross and Fine Motor Function (GMFM-88 full scale)

    Gross and Fine Motor Function (GMFM-88 full scale) - Change in Total Score from Baseline.

    Time frame: 156 weeks

  4. Disease Severity (Spastic Paraplegia Rating Scale )

    Disease Severity (Spastic Paraplegia Rating Scale ). Change in Total Score from Baseline.

    Time frame: 156 weeks

  5. Disease Severity (Clinical Global Impression)

    Disease Severity (Clinical Global Impression) Change in Physician-assessed Clinical Global Impression) from Baseline.

    Time frame: 156 weeks

  6. Muscle Spasticity (Modified Ashworth Scale)

    Change from Baseline in Muscle Spasticity (Modified Ashworth Scale) Score

    Time frame: 156 weeks

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Agianda HAP, Kim HM, Battaglia N, Rong J, Tam A, Gonzalez Saez-Diez E, Boerkoel CF, Saffari A, Quiroz V, Schierbaum L, Zaman Z, Bernardi K, Ebrahimi-Fakhari D. Diagnostic Utility of the ATG9A Ratio in AP-4-Associated Hereditary Spastic Paraplegia. Ann Clin Transl Neurol. 2026 Apr;13(4):834-839. doi: 10.1002/acn3.70308. Epub 2026 Jan 5. PubMed 41491634 ↗

Individual participant data

Plan to share: Yes — Will be posted on Elpida Therapeutics website

Supporting information: Study protocol, Clinical study report

Time frame: 12 months after start date for protocol. CSR 12 months after completion of study

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Feb 2032, 70 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2024
First posted
Nov 18, 2024
StartActual
Apr 1, 2026
Primary completionEst.
Feb 28, 2032
CompletionEst.
Jun 1, 2032
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06692712
Lead sponsor
Elpida Therapeutics SPC
Collaborators
University of Texas Southwestern Medical Center, Hospital Sant Joan de Deu
Responsible party
Sponsor
First posted
Nov 18, 2024
Start date
Apr 1, 2026
Primary completion
Feb 28, 2032 (estimated)
Completion
Jun 1, 2032 (estimated)
Last update
Apr 20, 2026

Study contacts

Rachel Thomas
Contact
studyinfo@elpidatx.com
+1-833-335-7432

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion